Reviva Pharmaceuticals Holdings (RVPH) Share-based Compensation (2021 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Share-based Compensation of $584439.0 for Q1 2026, up 36.8% sequentially from $427225.0 in Q4 2025, and down 36.41% YoY from $919119.0 in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Share-based Compensation (2021 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Share-based Compensation for 6 years, with the latest figure at $584439.0 in Q1 2026.
- Quarterly Share-based Compensation fell 36.41% year-over-year to $584439.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 12.0% YoY) and the FY2025 annual result came in at $2.2 million, down 4.35% from the prior year.
- Share-based Compensation improved to $584439.0 in Q1 2026 per RVPH's latest filing, from $427225.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.6 million in Q2 2023 and troughed at $39686.0 in Q1 2022.
- A 5-year average of $636619.6 and a median of $400000.0 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation surged 6420.21% in 2023, then plunged 84.62% in 2024.
- Over 5 years, Share-based Compensation stood at $79851.0 in 2022, then surged by 417.66% to $413354.0 in 2023, then climbed by 28.3% to $530341.0 in 2024, then declined by 19.44% to $427225.0 in 2025, then jumped by 36.8% to $584439.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $584439.0, $427225.0, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | 214,565.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 214,565.00 |
| Jun 30, 2026 | 214,565.00 |
| Mar 31, 2026 | 584,439.00 |
| Mar 31, 2026 | 584,439.00 |
| Dec 31, 2025 | 427,225.00 |
| Dec 31, 2025 | 427,225.00 |
| Sep 30, 2025 | 1.60 Mn |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 1.90 Mn |
| Mar 31, 2025 | 919,119.00 |
| Mar 31, 2025 | 919,119.00 |
| Dec 31, 2024 | 530,341.00 |
| Dec 31, 2024 | 530,341.00 |
| Sep 30, 2024 | 348,056.00 |
| Sep 30, 2024 | 348,056.00 |
| Jun 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |